Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Gliosarcoma 4Glioblastoma 4Sarcoma, Ewing 2Oligodendroglioma 2Glioma, Subependymal 2Glioma 2Ependymoma 2Astrocytoma 2Rhabdomyosarcoma 1Pinealoma 1Neuroectodermal Tumors, Primitive 1Meningioma 1Medulloblastoma 1Craniopharyngioma 1Choroid Plexus Neoplasms 1Carcinosarcoma 1Brain Neoplasms 1

Interventions

Temozolomide 48Bevacizumab 29Carmustine 17Erlotinib Hydrochloride 16Radiotherapy 14Irinotecan 14Surgical Procedures, Operative 10Sirolimus 10Imatinib Mesylate 10Carboplatin 10Sorafenib 9O(6)-benzylguanine 9Filgrastim 9Etoposide 8temsirolimus 7sargramostim 7Radiosurgery 7Radiation 7Procarbazine 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7aldesleukin 6Topotecan 6Thalidomide 6Vorinostat 5Thiotepa 5Peripheral Blood Stem Cell Transplantation 5Hydroxyurea 5Gefitinib 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Congresses as Topic × Sarcoma × Clear all
NCT00238303 2014-05-23

Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2 Completed
103 enrolled 10 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡